Aarkstore - Glutamate Receptor Antagonists -Pipeline Insights, 2014 - PowerPoint PPT Presentation

Loading...

PPT – Aarkstore - Glutamate Receptor Antagonists -Pipeline Insights, 2014 PowerPoint presentation | free to download - id: 6c0e9d-YTQxO



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Aarkstore - Glutamate Receptor Antagonists -Pipeline Insights, 2014

Description:

DelveInsights,Glutamate Receptor Antagonists-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Glutamate Receptor Antagonist – PowerPoint PPT presentation

Number of Views:6

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Aarkstore - Glutamate Receptor Antagonists -Pipeline Insights, 2014


1
Glutamate Receptor Antagonists -Pipeline
Insights, 2014
Category Pharmaceuticals Healthcare 
  • Browse Complete Report -
  • http//www.aarkstore.com/pharmaceuticals-healthcar
    e/73728/glutamate-receptor-antagonists-pipeline-in
    sights-2014

2
Summary
  • DelveInsights,Glutamate Receptor
    Antagonists-Pipeline Insights, 2014, report
    provides comprehensive insights about pipeline
    drugs across this mechanism of action (MOA). A
    key objective of the report is to establish the
    understanding for all the pipeline drugs that
    fall under Glutamate Receptor Antagonists. This
    report provides information on the therapeutic
    development based on the Glutamate Receptor
    Antagonists dealing with mechanism of action,
    comparative analysis at various stages covering
    Filed, Phase III, Phase II, Phase I, IND filed,
    Preclinical, Discovery and unknown stages,
    therapeutics assessment by monotherapy and
    combination products and molecule type drug
    information. The report also covers the companies
    information involved in the therapeutic
    development of the products. It also has
    highlighted the discontinued and dormant
    products. 

3
Summary
  • Data Sources The report is built using data and
    information sourced from proprietary databases,
    primary and secondary research and in-house
    analysis by DelveInsight team of industry
    experts. Secondary sources information and data
    has been collected from various printable and
    non-printable sources like search engines, News
    websites, Government Websites, Trade Journals,
    White papers, Magazines, Trade associations,
    Books, Industry Portals, Industry Associations
    and access to available databases. Please note
    this report requires certain updates. We have all
    the information available but require 3 business
    days to complete the process and ensure it is as
    up-to-date as possible. Certain sections in the
    report may be removed or altered based on the
    availability and relevance of data for the
    indicated mechanism of action. 

4
Summary
  • Scope  The report provides a snapshot of the
    global therapeutic landscape of Glutamate
    Receptor Antagonists The report provides pipeline
    products under drug profile section which
    includes product description, MOA, licensors
    collaborators, development partner and chemical
    information Coverage of the Glutamate Receptor
    Antagonists pipeline on the basis of target, MOA,
    route of administration, technology involved and
    molecule type The report reviews key players
    involved in the therapeutics development for
    Glutamate Receptor Antagonists and also provide
    company profiling The report also gives the
    information of dormant and discontinued pipeline
    projects  Pipeline products coverage based on
    various stages of development ranging from
    preregistration till discovery and undisclosed
    stages  Provides pipeline assessment by
    monotherapy and combination therapy products,
    stage of development and molecule type

5
Summary
  • Reasons to buy Complete MOA intelligence and
    complete understanding over therapeutics
    development for Glutamate Receptor
    Antagonists Identify the relationship between the
    drugs and use it for target finding, drug
    repurposing, and precision medicine. Devise
    corrective measures for pipeline projects by
    understanding Glutamate Receptor Antagonists
    pipeline depth and focus of Indication
    therapeutics  Developing strategic initiatives to
    support your drug development activities. Optimize
    your portfolio and keep you in touch with the
    rapidly changing pharmaceutical markets, and make
    the best decisions for your business.

6
Report Methodology 
  • Develop and design in licensing and out licensing
    strategies by identifying prospective partners
    with the most attractive projects to enhance and
    expand business potential and Scope Provides
    strategically significant competitor information,
    analysis, and insights to formulate effective RD
    development strategies  Modify the therapeutic
    portfolio by identifying discontinued projects
    and understanding the factors that drove them
    from pipeline Gaining a Full Picture of the
    Competitive Landscape for Evidence based Decisions

Browse Complete Report - http//www.aarkstore.com/
pharmaceuticals-healthcare/73728/glutamate-recepto
r-antagonists-pipeline-insights-2014
7
Table of Content
  • Glutamate Receptor Antagonists Overview Glutamate
    Receptor Antagonists Disease Associated Glutamate
    Receptor Antagonists Pipeline Therapeutics Glutama
    te Receptor Antagonists Therapeutics under
    Development by Companies  Glutamate Receptor
    Antagonists Late Stage Products (Filed and Phase
    III) Comparative Analysis  Glutamate Receptor
    Antagonists Mid Clinical Stage Products (Phase
    II) Comparative Analysis  Glutamate Receptor
    Antagonists Early Clinical Stage Products (Phase
    I and IND Filed) Comparative Analysis  Glutamate
    Receptor Antagonists Discovery and Pre-Clinical
    Stage Products  Comparative Analysis  Drug
    Candidate Profiles

8
List of Tables
  • Number of Products under Development for
    Glutamate Receptor Antagonists by Therapy Area,
    2014 Number of Products under Development for
    Glutamate Receptor Antagonists, 2014 Number of
    Products under Development by Companies  Comparati
    ve Analysis by Late Clinical Stage Products
    (Filed and Phase III), 2014 Comparative Analysis
    Mid Clinical Stage Products (Phase II),
    2014 Comparative Analysis Early Clinical Stage
    Products (Phase I and IND Filed),
    2014 Comparative Analysis Discovery and
    Pre-Clinical Stage Products, 2014 Drug Candidates
    Profiles Glutamate Receptor Antagonists
    Assessment by Monotherapy Products  Glutamate
    Receptor Antagonists Assessment by Combination
    Products  Glutamate Receptor Antagonists
    Assessment by Route of Administration 

9
List of Tables
  • Glutamate Receptor Antagonists Assessment by
    Stage and Route of Administration  Glutamate
    Receptor Antagonists Assessment by Molecule
    Type  Glutamate Receptor Antagonists Assessment
    by Stage and Molecule Type  Glutamate Receptor
    Antagonists Therapeutics Discontinued
    Products  Glutamate Receptor Antagonists
    Therapeutics Dormant Products Products under
    Development by Companies, 2014

10
List of Figures
  • Number of Products under Development for
    Glutamate Receptor Antagonists by Therapy Area,
    2014 Number of Products under Development for
    Glutamate Receptor Antagonists, 2014 Late
    Clinical Stage Products (Filed and Phase III),
    2014 Mid Clinical Stage Products (Phase II),
    2014 Early Clinical Stage Products (Phase I and
    IND Filed), 2014 Discovery and Pre-Clinical Stage
    Products, 2014 Glutamate Receptor Antagonists
    Assessment by Monotherapy Products  Glutamate
    Receptor Antagonists Assessment by Combination
    Products  Glutamate Receptor Antagonists
    Assessment by Route of Administration  Glutamate
    Receptor Antagonists Assessment by Stage and
    Route of Administration  Glutamate Receptor
    Antagonists Assessment by Molecule
    Type  Glutamate Receptor Antagonists Assessment
    by Stage and Molecule Type

11
Related Reports
  • OncoPlex Diagnostics - Pharmaceuticals
    Healthcare - Deals and Alliances Profile
  • MetaStat, Inc. - Pharmaceuticals Healthcare -
    Deals and Alliances Profile
  • Advanced Cell Diagnostics, Inc. - Pharmaceuticals
    Healthcare - Deals and Alliances Profile
  • Recordati S.p.A. (REC) - Pharmaceuticals
    Healthcare - Deals and Alliances Profile
  • Ascension Health - Pharmaceuticals Healthcare
    - Deals and Alliances Profile

12
  • Glutamate Receptor Antagonists -Pipeline
    Insights, 2014
  • Published Dec. 2014 60 Pages
  • DelveInsights,Glutamate Receptor
    Antagonists-Pipeline Insights, 2014, report
    provides comprehensive insights about pipeline
    drugs across this mechanism of action (MOA).
    Price

Format Price
PDF 1250
Site Licence 2500
Enterprise Wide Licence 4000
13
Contact Us
Office Office No. - 809, 8th Floor, B-Wing,
Mahaavir Icon,  Plot No.- 89 90,
Sector-15, CBD-Belapur, Navi Mumbai
400614,  Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953
  • You Can Visit http//www.aarkstore.com
  • OR Mail us at contact_at_aarkstore.com
  • Blog
  • http//www.aarkstore.com/blog/
  • Conference
  • http//conference.aarkstore.com/
  • News
  • http//www.aarkstore.com/news
About PowerShow.com